Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1244-1250

  Gerschenson, Mariana ^a   Kim, Courtney ^a   Berzins, Baiba ^b   Taiwo, Babafemi ^b   Libutti, Daniel E ^a   Choi, Julia ^a   Chen, Diana ^a   Weinstein, Jill ^b   Shore, Jessica ^b   Da Silva, Barbara ^c   Belsey, Elizabeth ^d   McComsey, Grace A ^e   Murphy, Robert L ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

^d Sigma Clinical   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Adipose; HIV; Lipodystrophy; Metabolic; Mitochondria

Indexed keywords

8 OXO DEOXYGUANINE; CHOLESTEROL; GLUCOSE; GLUTATHIONE; ISOPROSTANE DERIVATIVE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; CELL STRUCTURE; CLINICAL ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; GLUTATHIONE METABOLISM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; ICOSANOID METABOLISM; LIPID ANALYSIS; LIPID STORAGE; MALE; MITOCHONDRIAL DNA REPLICATION; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL EXAMINATION; SUBCUTANEOUS FAT; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION;

ADENINE; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; DEOXYGUANOSINE; F2-ISOPROSTANES; GLUTATHIONE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LAMIVUDINE; MALE; MITOCHONDRIA; PHOSPHONIC ACIDS; PYRIMIDINONES; RITONAVIR; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 65749093276     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp100     Document Type: Article

References (40)

1. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004; 4: 763-77.
2. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998; 339: 1296.
3. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
4. Madge S, Kinloch-de-Loes S, Mercey D et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13: 735-7.
5. Carr A, Miller J, Law M et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-32.
6. Haubrich RH, Riddler S, DiRienzo G et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 2007. Abstract 38, p. 78. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
7. Cameron DW, da Silva BA, Arribas JR et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198: 234-40.
8. Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007; 48: 166-72.
9. Shikuma CM, Hu N, Milne C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801-9.
10. Nolan D, Hammond E, Martin A et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38.
11. Gerschenson M, Shiramizu B, LiButti DE et al. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005; 10 Suppl 2: M83-9.
12. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
13. Garcia-Benayas T, Blanco F, de la Cruz JJ et al. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003; 17: 921-4.
14. John M, McKinnon EJ, James IR et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33: 29-33.
15. McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70.
16. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-23.
17. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
18. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
19. Claas GJ, Julg B, Goebel FD et al. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients. Eur J Med Res 2007; 12: 54-60.
20. AIDS Clinical Trials Group. Diagnostic Criteria for Abnormalities of Fat Distribution. http://www.actgnetwork.org (10 March 2009, date last accessed).
21. Shiramizu B, Shikuma KM, Kamemoto L et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32: 370-4.
22. Anson RM, Bohr VA. Gene-specific and mitochondrial repair of oxidative DNA damage. Methods Mol Biol 1999; 113: 257-79.
23. Anson RM, Mason PA, Bohr VA. Gene-specific and mitochondrial repair of oxidative DNA damage. Methods Mol Biol 2006; 314: 155-81.
24. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
25. Medina DJ, Tsai CH, Hsiung GD et al. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994; 38: 1824-8.
26. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49 3-8.
27. Hashiguchi K, Bohr VA, de Souza-Pinto NC. Oxidative stress and mitochondrial DNA repair: Implications for NRTIs induced DNA damage. Mitochondrion 2004; 4: 215-22.
28. de la Asuncion JG, del Olmo ML, Sastre J et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998; 102: 4-9.
29. de la Asuncion JG, del Olmo ML, Sastre J et al. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology 1999; 29: 985-7.
30. Bialkowska A, Bialkowski K, Gerschenson M et al. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT). Carcinogenesis 2000; 21 1059-62.
31. Iwamoto T, Hiraku Y, Oikawa S et al. Oxidative DNA damage induced by photodegradation products of 3(′)-azido-3(′ -deoxythymidine. Arch Biochem Biophys 2003; 416: 155-63.
32. Jocelyn PC, Dickson J. Glutathione and the mitochondrial reduction of hydroperoxides. Biochim Biophys Acta 1980; 590: 1-12.
33. Esteve JM, Mompo J, Garcia de la Asuncion J et al. Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro. FASEB J 1999; 13: 1055-64.
34. Morrow JD, Roberts LJ II. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996; 51: 1-9.
35. Wang Z, Ciabattoni G, Creminon C et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
36. McComsey GA, Morrow JD. Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 2003; 34: 45-9.
37. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
38. Milinkovic A, Martinez E, Lopez S et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12: 407-15.
39. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002; 288: 207-15.
40. Cherry CL, Lal L, Thompson KA et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005; 38: 263-7.